AB&B Bio-Tech CO., LTD. JS (the “Company”) on 30 June 2026 issued a quarterly progress report on its trading resumption plan, announced the postponement of its 2025 annual general meeting (AGM), and confirmed that trading in its H shares will remain suspended.
Resumption guidance from the Hong Kong Stock Exchange requires the Company to: 1) complete an independent forensic investigation into questioned fund investments and consultancy payments and disclose the findings; 2) demonstrate the integrity and competence of management and controlling parties; 3) rectify internal-control deficiencies through an external review and confirm Listing Rules compliance; 4) publish all outstanding financial results and address any audit modifications; 5) prove ongoing compliance with Listing Rule 13.24 (sufficient operations and assets); and 6) release all material information necessary for investor assessment.
Progress to date: • Forensic investigation – Baker Tilly Aranea Forensic Investigation Company Limited has begun work; results will be announced upon completion. • Internal-control review – Cheng & Cheng Risk Advisory Services Limited is conducting an independent review focused on fund investments and consultancy payments; findings will be released when available. • Outstanding 2025 audit – Following Deloitte Touche Tohmatsu’s 13 April 2026 resignation, Prism Hong Kong Limited was appointed auditor on 27 May 2026. Audit procedures on FY2025 results, including confirmations, voucher reviews and valuations, are under way. Publication dates for the audited 2025 results and a rescheduled Board meeting will be announced separately.
Operational update: AB&B Bio-Tech reports that vaccine R&D, manufacturing and commercial activities—including quadrivalent and trivalent subunit influenza vaccines and a lyophilized human rabies vaccine candidate—continue at normal levels. The Board states that existing assets and operations remain sufficient to support the Company’s listing status.
Governance timetable: Owing to the delay in releasing FY2025 results, the statutory AGM—originally required by 30 June 2026—has been postponed until further notice. A new meeting date will be communicated after financial statements are ready.
Trading status: The Company’s H shares have been suspended since 09:00 on 1 April 2026 and will stay suspended pending fulfilment of the Stock Exchange’s resumption conditions. Shareholders and investors are urged to exercise caution when dealing in the Company’s securities.
Comments